Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

NCT05176002 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Neoplasm
Immunotherapy
Radiotherapy

Interventions

DRUG: Camrelizumab

Sponsor

Fujian Medical University Union Hospital